A Phase II, Single-arm, Open-label Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed While Receiving HER2-Directed Therapy
收藏DataCite Commons2026-03-03 更新2024-07-13 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00005720/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
This was a multi-institutional, open-label, single-arm, Phase II study of trastuzumab emtansine (T-DM1) administered by intravenous (IV) infusion to patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC).
提供机构：
Vivli
创建时间：
2020-05-05
